🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 6 of 173

  1. US 12252464

    Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12251379

    Methods of inhibiting formation of alpha synuclein aggregates

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12251370

    Small molecule inhibitors of the BfrB:Bfd interaction

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12251449

    Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12246056

    Compositions and methods for the production of cysteine

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12246057

    Transmembrane stem cell factor (tm-SCF) lipid nanocarriers and methods of use thereof

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12246011

    Radiation mitigator and method of use thereof

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12246096

    Self-assembled microcapsules with stimuli-responsive organic ligands

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12247978

    Compositions and methods for detection and treatment of coronavirus infection

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12247973

    Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12247213

    Treatment of mucopolysaccharidosis IVA

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12246086

    Applications and imaging of shear-thinning biomaterial

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12240852

    Co-crystals, method and apparatus for forming the same

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12241099

    Peptide therapeutics for treating Alzheimer's disease and related conditions

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12239694

    Methods and compositions for improved cognition

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12241902

    Probes for detection of copper

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12234461

    Targeted non-viral DNA insertions

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12234474

    Method to prevent the myelin abnormalites associated with arginase deficiency

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12234480

    Therapeutic methods involving modulating inflammasome activation of myeloid-derived suppressor cells

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12233073

    Skin care formulations and skin cancer treatment

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12233063

    Compositions and methods for treating eye disorders

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12233090

    Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12234516

    Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12234260

    Virus-like nanoparticles for oral delivery

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12233086

    Biomarkers for neurogenerative disease

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12233188

    Bone marrow adipose portion isolation device and methods

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12234263

    Influenza vaccines

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12233241

    Methods and systems to validate physiologic waveform reliability and uses thereof

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12233150

    Oral care compositions comprising star-shaped polymers

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12233129

    Methods and compositions for the treatment of cancer

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12227581

    Anti-BCMA single domain antibodies and application thereof

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12226489

    Compounds and methods for treating gastrointestinal disease

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12226488

    Nitroreductase-releasable pro-drugs and methods for using the same

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12226404

    Methods for making compositions for pulmonary administration

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12226524

    Coated implants for long-term controlled release of antibody therapeutics

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12226450

    Peptides and methods for treating disease

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12227503

    Compositions and methods for modulating hair growth

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12226386

    Compositions and methods for treating biofilms

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12227547

    Modulators of CAS9 polypeptides and methods of use thereof

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12226546

    Polyion complex polypeptide hydrogels and uses thereof

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12227562

    Compositions and methods to treat viral infection and co-morbidities

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12226491

    Nano-satellite complexes

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12227482

    Compounds and compositions for the treatment of cancer

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12226435

    Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12220421

    Inhibitors of C. difficile spore germination

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12220389

    Combination therapy for the treatment of tinnitus and other medical conditions

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12221622

    Modified pluripotent cells

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.